Precision medicine tailors therapeutics to individual patients diseases, and is seen as the future of clinical practice. With significant time and financial investments being made in developing therapeutics, the ultimate success of patient-data driven precision therapies hinges on three main factors: the quality of the tissue samples, the associated molecular data, and the analysis used in their development.
Orakl Oncology SA raises €3m to advance tumour modelling
Latest NewsParis-based Orakl Oncology SA has raised €3m to develop its techbio platform for precision oncology.
Precision therapeutics: optimising early discovery
BackgroundPrecision medicine tailors therapeutics to individual patients diseases, and is seen as the future of clinical practice. With significant time and financial investments being made in developing therapeutics, the ultimate success of patient-data driven precision therapies hinges on three main factors: the quality of the tissue samples, the associated molecular data, and the analysis used in their development.
BioM drives innovation in biotech
Sponsored PublicationsFor 25 years now, BioM has been the network organisation of the biotechnology sector in Munich and Bavaria. To shape the future of biotechnology, BioM identifies relevant and sustainable local, regional and global trends and creates a unique ecosystem for innovation and growth.
Sanofi licences vaccine against bacterial sepsis
Latest NewsFrench pharma major Sanofi SA will pay US$175m upfront to Janssen Pharmaceuticals, Inc. for commercialisation of a Phase III vaccine against extraintestinal pathogenic E. coli.
Spain set to unveil the potential of the biologisation of medicine and food production
Latest NewsThe Spanish EU Council Presidency is to set the course for the internationally competitive use of biotechnology in drug development, plant breeding and food production.
Spain: An overview over a sector that has proven to be strategic
BackgroundAfter two years of unprecedented growth driven by the pandemic, investment attracted by Spanish biotech companies has stabilised, and they face significant challenges, positioning biotechnology as a strategic sector for Spain.
Mogrify Ltd extends Series A financing to $46m
Latest NewsBritish in-vivo cell programming specialist Mogrify Ltd has added US$10m to its US$36m Series A financing.
Seamless Transition: Elevate Immune Cell Expansion from RUO to GMP
ProductsCell Culture Grade AB Serum that can be customised to your specifications.
Joining forces for mRNA breakthrough
Latest NewsDyadic International Inc. and bYoRNA SAS partnered to advance innovative bioproduction technologies for scaling up the production of therapeutic mRNA from C1-Cells.
‘Older & Fatter’ megatrend is a time waster
OpinionStock markets love investment concepts, calling the robust ones ‘megatrends’. Golden ageing is one such megatrend banking on the fact that business can extract more from people living longer. Such megatrend investments help – up to the moment when rising interest rates crash the party.